Drug repurposing approach to fight COVID-19
Currently, there are no treatment options available for the deadly contagious disease,
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
Long‐COVID syndrome‐associated brain fog and chemofog: Luteolin to the rescue
TC Theoharides, C Cholevas, K Polyzoidis… - Biofactors, 2021 - Wiley Online Library
COVID‐19 leads to severe respiratory problems, but also to long‐COVID syndrome
associated primarily with cognitive dysfunction and fatigue. Long‐COVID syndrome …
associated primarily with cognitive dysfunction and fatigue. Long‐COVID syndrome …
SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB
SARS-CoV-2 is a novel virus that has rapidly spread, causing a global pandemic. In the
majority of infected patients, SARS-CoV-2 leads to mild disease; however, in a significant …
majority of infected patients, SARS-CoV-2 leads to mild disease; however, in a significant …
Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19
H Satış, HS Özger, PA Yıldız, K Hızel, Ö Gulbahar… - Cytokine, 2021 - Elsevier
Background The effectual immune response is crucial to defeat viral infections. However,
exuberant immune response with features of macrophage activation syndrome (MAS) lead …
exuberant immune response with features of macrophage activation syndrome (MAS) lead …
Natural killer cell dysfunction and its role in COVID-19
When facing an acute viral infection, our immune systems need to function with finite
precision to enable the elimination of the pathogen, whilst protecting our bodies from …
precision to enable the elimination of the pathogen, whilst protecting our bodies from …
Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma
D Kempuraj, R Thangavel, DD Kempuraj… - Biofactors, 2021 - Wiley Online Library
Neuroinflammation leads to neurodegeneration, cognitive defects, and neurodegenerative
disorders. Neurotrauma/traumatic brain injury (TBI) can cause activation of glial cells …
disorders. Neurotrauma/traumatic brain injury (TBI) can cause activation of glial cells …
IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression
Abstract Aims SARS-CoV-2, an infectious agent behind the ongoing COVID-19 pandemic,
induces high levels of cytokines such as IL-1, IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ etc in …
induces high levels of cytokines such as IL-1, IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ etc in …
Role of SARS-CoV-2 spike-protein-induced activation of microglia and mast cells in the pathogenesis of neuro-COVID
TC Theoharides, D Kempuraj - Cells, 2023 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus
disease 2019 (COVID-19). About 45% of COVID-19 patients experience several symptoms a …
disease 2019 (COVID-19). About 45% of COVID-19 patients experience several symptoms a …
Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study
P Monedero, A Gea, P Castro, AM Candela-Toha… - Critical Care, 2021 - Springer
Background Critically ill patients with coronavirus disease 19 (COVID-19) have a high
fatality rate likely due to a dysregulated immune response. Corticosteroids could attenuate …
fatality rate likely due to a dysregulated immune response. Corticosteroids could attenuate …
[HTML][HTML] A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
The emergence of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout …